Press Release | NeoGenomics Laboratories

February 2, 2022

NeoGenomics Schedules its Fourth Quarter and Full Year 2021 Earnings Release for February 23, 2022

January 24, 2022

NeoGenomics First to Partner with Biomarker Collaborative and Deliver Patient Resources Along with Oncology Testing Results

January 11, 2022

NeoGenomics Announces RaDaR(TM) Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX Program

December 13, 2021

NeoGenomics Appoints David Eberhard MD, PhD as Chief Medical Officer of Inivata Liquid Biopsy Subsidiary

December 10, 2021

NeoGenomics to Leverage Thermo Fisher Scientific’s Ion Torrent Genexus System in Upcoming Phase 1 Study for Myeloid Cancers

November 30, 2021

NeoGenomics To Participate In The Stephens Annual Investment Conference 2021

November 10, 2021

NeoGenomics Appoints Dave Daly to Its Board of Directors

November 4, 2021

NeoGenomics Announces Leadership Team Transition

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients